8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 1, 2006
Date of Report (Date of Earliest Event Reported)

ALLERGAN, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware
(State of Incorporation) 1-10269
(Commission File Number) 95-1622442
(IRS Employer
Identification Number)

2525 Dupont Drive
Irvine, California 92612
(Address of Principal Executive Offices) (Zip Code)

(714) 246-4500
(Registrant’s Telephone Number, Including Area Code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 1.01. Entry into a Material Definitive Agreement.
	Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Exhibit Index
EXHIBIT 10.1

Item 1.01. Entry into a Material Definitive Agreement.

Allergan, Inc. 2006 Executive Bonus Plan

On January 30, 2006, the Board of Directors (the “Board”) of Allergan, Inc. (the “Company”) approved the adoption of the 2006 Executive Bonus Plan (the “Executive Bonus Plan”), subject to approval by the Company’s stockholders. On May 2, 2006, the Executive Bonus Plan became effective upon approval by the Company’s stockholders at the Company’s 2006 Annual Meeting of Stockholders (the “2006 Annual Meeting”).

The Executive Bonus Plan replaces the bonus plan for the Chief Executive Officer approved by the Company’s stockholders in 1999, and authorizes the Organization and Compensation Committee of the Board to establish annual bonus programs based on specified performance objectives for the Chief Executive Officer and the President. The foregoing description of the Executive Bonus Plan is qualified in its entirety by the Executive Bonus Plan, a copy of which was included as Appendix B to the Company’s definitive proxy statement (the “2006 Proxy Statement”) for the 2006 Annual Meeting, which was filed with the Securities and Exchange Commission on March 21, 2006 and is incorporated herein by reference. A more detailed description of the Executive Bonus Plan may also be found in the 2006 Proxy Statement in the section entitled “Proposal Four—Approval of the Allergan, Inc. 2006 Executive Bonus Plan,” which is incorporated herein by reference.

Amendment to the Allergan, Inc. 2003 Non-Employee Director Equity Incentive Plan

On January 30, 2006, the Board approved an amendment (the “Plan Amendment”) to the Allergan, Inc. 2003 Non-employee Director Equity Incentive Plan (the “Director Plan”), subject to approval by the Company’s stockholders, as a means to attract and retain the services of experienced and knowledgeable non-employee directors to serve on the Board, to increase the proprietary interests of the Company’s non-employee directors in the Company and to enable the Company to continue to provide a total package of non-employee director compensation competitive with comparable publicly-traded companies. The Plan Amendment became effective on May 2, 2006, upon approval by the Company’s stockholders at the 2006 Annual Meeting.

The Plan Amendment modifies the Director Plan to: (i) increase the number of shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), reserved for issuance under the Director Plan from 500,000 shares to 850,000 shares; (ii) eliminate the restriction in the Director Plan that only up to 250,000 shares available for issuance under the Director Plan may be issued in the form of restricted stock awards and provide that all shares available under the Director Plan may be issued in the form of stock options or restricted stock; and (iii) increase the annual grant of nonqualified stock options to non-employee directors to an option to purchase 4,500 shares of Common Stock from an option to purchase 2,500 shares of Common Stock, beginning with the 2006 Annual Meeting. The foregoing description of the Plan Amendment is qualified in its entirety by the Plan Amendment, a copy of which was included as Appendix A to the 2006 Proxy Statement and is incorporated herein by reference. A more detailed description of the Plan Amendment may also be found in the 2006 Proxy Statement in the section entitled “Proposal Three—Approval of an Amendment to the Allergan, Inc. 2003 Non-Employee Director Equity Incentive Plan,” which is incorporated herein by reference.

Allergan, Inc. 2006 Management Bonus Plan

     The Board approved an adjusted and amended Allergan, Inc. 2006 Management Bonus Plan (the “Revised Bonus Plan”) on May 1, 2006, which became effective on that date.

2

The Revised Bonus Plan amends the performance criteria established under the Allergan, Inc. 2006 Management Bonus Plan to add Inamed Corporation’s (“Inamed”) revenues and employees, as applicable, to the Bonus Plan following the completion of the Company’s acquisition of Inamed on March 23, 2006. The Revised Bonus Plan also adjusts certain retirement features under the Bonus Plan and certain bonus categories. The foregoing description of the Revised Bonus Plan is qualified in its entirety by the Revised Bonus Plan, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

10.1 Allergan, Inc. 2006 Management Bonus Plan

3

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALLERGAN, INC.
Date: May 5, 2006	By:	/s/ Matthew J. Maletta
	Name:	Matthew J. Maletta
	Title:	Vice President, Assistant General Counsel and Assistant Secretary

Exhibit Index

Exhibit	Description of Exhibit
10.1	Allergan, Inc. 2006 Management Bonus Plan.

EX-10.1

Exhibit 10.1

ALLERGAN

2006

MANAGEMENT BONUS PLAN
 

PURPOSE OF THE PLAN

The Allergan, Inc. 2006 Management Bonus Plan (the “Plan”) is designed to reward eligible management-level employees for their contributions to providing Allergan’s stockholders increased value for their investment through the successful accomplishment of specific financial objectives and individual performance objectives.

PLAN YEAR

The Plan year runs from January 1, 2006 through December 31, 2006.

ELIGIBILITY

All regular full-time and part-time employees of Allergan, Inc. and its subsidiaries (the “Company”) scheduled to work 20 or more hours per week in salary grades 7E and above who are not covered by any other bonus or sales incentive plan are eligible to participate in the Plan. Notwithstanding anything in this Plan to the contrary, any individual shall not be eligible to participate in the Plan if such individual (a) performs services for the Company and is classified or paid as an independent contractor (regardless of his or her classification for federal tax or other legal purposes) by the Company or (b) performs services for the Company pursuant to an agreement between the Company and any other person including a leasing organization. Participants must be employed on or before June 30, 2006 in order to be eligible to receive a bonus. Participants must be actively employed by the Company on the date bonuses are paid in order to be eligible to receive a bonus. Participants who resign or are terminated for reasons other than those noted below will receive no bonus.

Bonuses, if any, for participants who become eligible after the beginning of the plan year, retire (“normal retirement” is defined as termination of employment after the Plan participant has attained age 55, provided that such participant has been employed by the Company for a minimum of 5 years), become disabled, die or transfer into a position covered by another incentive plan will be prorated. Bonuses, if any, for participants who are laid-off will be prorated provided the participant was eligible for at least six months of the Plan year. All proration will be based on the number of months of participation in the Plan during the Plan year.

PERFORMANCE OBJECTIVES

Bonuses for Plan participants are based on both corporate performance and individual performance in relation to pre-established objectives, as follows:

CORPORATE OBJECTIVES

¨   Earnings Per Share (“EPS”)—EPS is defined as adjusted net earnings from continuing operations as measured by Wall Street divided by the weighted average number of common and common equivalent shares on a diluted basis.

¨   Sales Revenue Growth in Local Currency—Sales revenue stated in constant local currency compared to the prior year. Specifically defined as the percentage change in annual sales revenue in constant local currency from the previous fiscal year end to the current fiscal year end (“Revenue Growth”). The purpose of sales stated in constant local currency is to remove any impact on sales growth from changes in currency exchange rates from year to year.

¨   Research and Development (“R&D”) Reinvestment Rate—R&D expense as a percentage of revenue. Specifically defined as the total annual R&D expense as a percentage of annual pharmaceutical sales as of the current fiscal year end.

06 MBP Page -1-

¨   Operating Income—Operating Income compared to budget will be considered for allocation of bonus pools by Business Unit/Function. Operating Income is defined as Net Sales minus Cost of Goods minus Selling and General Administrative expenses minus Research & Development minus allocated corporate interest where applicable.

INDIVIDUAL OBJECTIVES

Management Bonus Objectives (“MBOs”) are prepared by each participant and his or her supervisor at the beginning of the Plan year and may be modified throughout the year as necessary. Objectives should reflect major results and accomplishments to be achieved in order to meet short and long-term business goals that contribute to increased stockholder value. MBOs are expressed as specific, quantifiable measures of performance in relation to key operating decisions for the participant’s business unit, such as managing inventory levels, receivables, expenses, payables, increasing sales, eliminating unnecessary capital expenditures, etc.

At the end of the Plan year, the supervisor evaluates the participant’s performance in relation to his or her objectives in order to determine the size of the bonus award, if any. A more detailed description of how the award is calculated is provided under “Individual Bonus Award Calculation.”

BONUS POOL CALCULATION

The components of this calculation for bonus pool funding are: (1) EPS, (2) Revenue Growth and (3) R&D Reinvestment Rate.

BONUS POOL FUNDING — Bonuses are funded when the Company achieves a threshold level of target EPS performance. The level of bonus funding is determined by EPS performance, Revenue Growth and R&D Reinvestment Rate as outlined in the table below.

¨   Earnings Per Share, Revenue Growth and R&D Reinvestment Rate

2006 EPS RANGE	BONUS % OF TARGET	REVENUE GROWTH	BONUS % OF TARGET	R&D REINVEST. RATE	BONUS % OF TARGET	TOTAL BONUS % OF TARGET
-$0.15	0.0%	25.9%	0.0%	14.49%	0.0%	0.0%
-$0.12	50.0%	26.9%	2.0%	14.74%	2.0%	54.0%
-$0.09	60.0%	27.9%	4.0%	14.99%	4.0%	68.0%
-$0.06	70.0%	28.9%	6.0%	15.24%	6.0%	82.0%
-$0.03	80.0%	29.9%	8.0%	15.49%	8.0%	96.0%
Target	90.0%	30.9%	10.0%	15.74%	10.0%	110.0%
$0.02	95.0%	31.9%	13.8%	15.99%	13.8%	122.5%
$0.04	100.0%	32.9%	17.5%	16.24%	17.5%	135.0%
$0.06	105.0%	33.9%	21.3%	16.49%	21.3%	147.5%
$0.08	110.0%	34.9%	25.0%	16.74%	25.0%	160.0%

Revenue Growth and R&D Reinvestment Rate bonus funding may not exceed target unless EPS performance is equal to or greater than target. If actual results fall between the performance levels shown above, bonuses will be prorated accordingly.

06 MBP Page -2-

BONUS POOL DIFFERENTIATION BY BUSINESS UNIT/FUNCTION

¨   Operating Income—The target bonus pool determined by EPS, Revenue Growth and R&D Reinvestment Rate performance is modified for each business unit/function based on Operating Income results vs. budget. That is, a business unit that exceeds budget will receive a greater share of the total Company pool than a business unit that is below budget.

At the end of the year, the Chief Executive Officer of Allergan, Inc. may recommend adjustments to the bonus funding levels to the Organization and Compensation Committee (the “Committee”) after consideration of key operating results. When calculating corporate performance for purposes of this Plan, the Committee has the discretion to include or exclude any or all of the following items:

• extraordinary, unusual or non-recurring items

• effects of accounting changes

• effects of financing activities

• expenses for restructuring or productivity initiatives

• other non-operating items

• spending for acquisitions

• effects of divestitures

• amortization of acquired intangible assets

INDIVIDUAL BONUS AWARD CALCULATION

Target bonus awards are expressed as a percentage of the participant’s year-end annualized base salary. The target percentages vary by salary grade (see Attachment No. 1).

A participant’s actual bonus award may vary above or below the targeted level based on the supervisor’s evaluation of his or her performance in relation to the predetermined MBOs. Each participant’s actual bonus award may be modified down to 0% or up to 150% of his or her target bonus amount. However, the total of all bonus awards given within each business unit must total no more than 100% of the total bonus pool dollars allocated to that business unit.

METHOD OF PAYMENT

For grade 8 Directors and above, bonuses are paid in cash up to a maximum bonus pool equal to 100% of participants’ bonus targets and performance over such pool is paid in restricted stock or restricted stock units with cliff vesting two years from the award effective date. Any payment in the form of stock will be issued under the Incentive Compensation Plan. Upon a recipient’s normal retirement eligibility date (defined as the date on which the recipient has (i) attained age 55 and (ii) been employed by the Company for a minimum of 5 years) all of the restrictions imposed on the recipient’s restricted stock shall lapse. For grade 7 participants, all bonuses are paid in cash. Bonus awards are paid following the close of the Plan year after the review and authorization of bonuses by the Committee. Bonuses will be paid within 30 days following management communication of the award, through the participant’s normal payroll channel. In the event of a Change in Control (as defined in Attachment No. 2), bonuses will be paid within 30 days of the effective date of the Change in Control.

06 MBP Page -3-

CHANGE IN CONTROL

If a Change in Control occurs after the close of the Plan year and Company performance supports bonus pool funding, participants will be paid a bonus based on performance in relation to the EPS, Revenue Growth and R&D Reinvestment Rate targets.

If the Change in Control occurs during the Plan year, participants will be paid a bonus prorated to the effective date of the Change in Control and EPS, Revenue Growth and R&D Reinvestment Rate performance will be deemed to be the greater of:

• 100% of the EPS, Revenue Growth and R&D Reinvestment Rate targets or

• the prorated actual year-to-date performance

In either case, a participant’s actual bonus may vary above or below the targeted level according to the provisions outlined in “Individual Bonus Award Calculation” above. Participants must be employed by the Company or its successor on the effective date of the Change in Control in order to receive the prorated payment, unless their employment is terminated for retirement, death, disability or otherwise without cause. For purposes of this plan, “cause” shall be limited to only three types of events: the willful refusal to comply with a lawful, written instruction of the Board so long as the instruction is consistent with the scope and responsibilities of the participant’s position prior to the Change in Control; dishonesty which results in a material financial loss to the Company (or to any of its affiliated companies) or material injury to its public reputation (or to the public reputation of any of its affiliated companies); or conviction of any felony involving an act of moral turpitude.

GENERAL

Management reserves the right to define corporate performance and individual performance and to review, alter, amend, or terminate the Plan at any time subject to approval of the Committee. This Plan does not constitute a contract of employment and cannot be relied upon as such. Any questions regarding this Plan should be directed to the Human Resources department or the Vice President, Compensation and Benefits. This Management Bonus Plan document supersedes any previous document you may have received.

06 MBP Page -4-

ATTACHMENT NO. 1

ALLERGAN

2006 MANAGEMENT BONUS PLAN

TARGET AWARDS

	US	Intl	Inamed Division
Salary Grade	Target Bonus	Target Bonus	Salary Grade	Target Bonus
7E	12%	15%	E19	15% - 17%
8E	17%	20%	E21	15% - 25%
9E	23%	25%
10E	25%	30%	E23	25%
11E	35%	35%	VP	30% - 50%
12E	35%	40%	VP	30% - 50%
13E	40%	45%	VP	30% - 50%
13E EVP	50%
14E	50%
15E	60%

06 MBP Page -5-

ATTACHMENT NO. 2

CHANGE IN CONTROL DEFINITION

“Change in Control” shall mean the following and shall be deemed to occur if any of the following events occur:

          (a) Any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (a “Person”), is or becomes the “beneficial owner,” as defined in Rule 13d-3 under the Exchange Act (a “Beneficial Owner”), directly or indirectly, of securities of Allergan, Inc., a Delaware corporation (“Allergan”) representing (i) 20% or more of the combined voting power of Allergan’s then outstanding voting securities, which acquisition is not approved in advance of the acquisition or within 30 days after the acquisition by a majority of the Incumbent Board (as hereinafter defined) or (ii) 33% or more of the combined voting power of Allergan’s then outstanding voting securities, without regard to whether such acquisition is approved by the Incumbent Board;

          (b) Individuals who, as of the date hereof, constitute the Board of Directors of Allergan (the “Incumbent Board”), cease for any reason to constitute at least a majority of the Board of Directors, provided that any person becoming a director subsequent to the date hereof whose election, or nomination for election by Allergan’s stockholders, is approved by a vote of at least a majority of the directors then comprising the Incumbent Board (other than an election or nomination of an individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of Allergan, as such terms are used Rule 14a-11 of Regulation 14A promulgated under the Exchange Act) shall, for the purposes of this Agreement, be considered as though such person were a member of the Incumbent Board of Allergan;

          (c) The consummation of a merger, consolidation or reorganization involving Allergan, other than one which satisfies both of the following conditions:

                    (1) a merger, consolidation or reorganization which would result in the voting securities of Allergan outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of another entity) at least 55% of the combined voting power of the voting securities of Allergan or such other entity resulting from the merger, consolidation or reorganization (the “Surviving Corporation”) outstanding immediately after such merger, consolidation or reorganization and being held in substantially the same proportion as the ownership in Allergan’s voting securities immediately before such merger, consolidation or reorganization, and

                    (2) a merger, consolidation or reorganization in which no Person is or becomes the Beneficial Owner directly or indirectly, of securities of Allergan representing 20% or more of the combined voting power of Allergan’s then outstanding voting securities; or

          (d) The stockholders of Allergan approve a plan of complete liquidation of Allergan or an agreement for the sale or other disposition by Allergan of all or substantially all of Allergan’s assets.

Notwithstanding the preceding provisions of this Section, a Change in Control shall not be deemed to have occurred if the Person described in the preceding provisions of this Section is (1) an underwriter or underwriting syndicate that has acquired the ownership of any of Allergan’s then outstanding voting securities solely in connection with a public offering of Allergan’s securities, (2) Allergan or any subsidiary of Allergan or (3) an employee stock ownership plan or other employee benefit plan maintained by Allergan (or any of its affiliated companies) that is qualified under the provisions of the Internal Revenue Code of 1986, as amended. In addition, notwithstanding the preceding provisions of this Section, a Change in Control shall not be deemed to have occurred if the Person described in the preceding provisions of this Section becomes a Beneficial Owner of more than the permitted amount of outstanding securities as a result of the acquisition of voting securities by Allergan which, by reducing the number of voting securities outstanding, increases the proportional number of shares beneficially owned by such Person, provided, that if a Change in Control would occur but for the operation of this sentence and such Person becomes the Beneficial Owner of any additional voting securities (other than through the exercise of options granted under any stock option plan of Allergan or through a stock dividend or stock split), then a Change in Control shall occur.

06 MBP Page -6-